<?xml version="1.0" encoding="UTF-8"?>
<p id="p0205">The high potency of mRNA vaccines with only one or two low dose immunization is capable of generating potent antiviral neutralizing antibodies by activating both CD4
 <sup>+</sup> and CD8
 <sup>+</sup> T cells [
 <xref rid="bib161" ref-type="bibr">161</xref>, 
 <xref rid="bib162" ref-type="bibr">162</xref>, 
 <xref rid="bib163" ref-type="bibr">163</xref>]. The structural modification of mRNA results in higher immunogenicity by improving its stability and translation efficacy [
 <xref rid="bib161" ref-type="bibr">161</xref>, 
 <xref rid="bib162" ref-type="bibr">162</xref>]. The potential risk of infection and insertion induced mutagenesis are minimized by mRNA based vaccines due to its natural degradation in cells [
 <xref rid="bib164" ref-type="bibr">164</xref>]. In order to treat large populations, engineered mRNA facilitates the large-scale production of the required vaccine dose [
 <xref rid="bib165" ref-type="bibr">165</xref>, 
 <xref rid="bib166" ref-type="bibr">166</xref>].
</p>
